|
1.
|
Krynetskaia NF, Phadke MS, Jadhav SH and
Krynetskiy EY: Chromatin-associated proteins HMGB1/2 and PDIA3
trigger cellular response to chemotherapy-induced DNA damage. Mol
Cancer Ther. 8:864–872. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: the metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI
|
|
3.
|
Ponisovskiy MR: Warburg effect mechanism
as the target for theoretical substantiation of a new potential
cancer treatment. Crit Rev Eukaryot Gene Expr. 21:13–28. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
5.
|
Toki N, Kagami S, Kurita T, et al:
Expression of mitochondrial transcription factor A in endometrial
carcinomas: clinicopathologic correlations and prognostic
significance. Virchows Arch. 456:387–393. 2010. View Article : Google Scholar
|
|
6.
|
Yoshida Y, Hasegawa J, Nezu R, et al:
Clinical usefulness of mitochondrial transcription factor A
expression as a predictive marker in colorectal cancer patients
treated with FOLFOX. Cancer Sci. 102:578–582. 2011. View Article : Google Scholar
|
|
7.
|
Kurita T, Izumi H, Kagami S, et al:
Mitochondrial transcription factor A regulates BCL2L1 gene
expression and is a prognostic factor in serous ovarian cancer.
Cancer Sci. 103:239–444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Tatarkova Z, Kuka S, Petráš M, et al: Why
mitochondria are excellent targets for cancer therapy. Klin Onkol.
25:421–426. 2012.PubMed/NCBI
|
|
9.
|
Li X, Zhang G, Luo F, et al:
Identification of aberrantly expressed miRNAs in rectal cancer.
Oncol Rep. 28:77–84. 2012.PubMed/NCBI
|
|
10.
|
He L, He X, Lim LP, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar
|
|
12.
|
Volinia S, Calin GA, Liu CG, et al: A
microRNA expression signature of human solid tumors defines cancer
gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Villa C, Fenoglio C, De Riz M, et al: Role
of hnRNP-A1 and miR-590-3p in neuronal death: genetics and
expression analysis in patients with Alzheimer disease and
frontotemporal lobar degeneration. Rejuvenation Res. 14:275–281.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Vinuesa CG, Rigby RJ and Yu D: Logic and
extent of miRNA-mediated control of autoimmune gene expression. Int
Rev Immunol. 28:112–138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Hermeking H: MicroRNAs in the p53 network:
micromanagement of tumour suppression. Nat Rev Cancer. 12:613–626.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Papaconstantinou IG, Lykoudis PM, Gazouli
M, Manta A, Polymeneas G and Voros D: A review on the role of
microRNA in biology, diagnosis, and treatment of pancreatic
adenocarcinoma. Pancreas. 41:671–677. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Majid S, Dar AA, Saini S, et al:
MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1
in bladder cancer. PLoS One. 7:e467432012. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Nordentoft I, Birkenkamp-Demtroder K,
Agerbæk M, et al: miRNAs associated with chemo-sensitivity in cell
lines and in advanced bladder cancer. BMC Med Genomics. 5:402012.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Vernochet C, Mourier A, Bezy O, et al:
Adipose-specific deletion of TFAM increases mitochondrial oxidation
and protects mice against obesity and insulin resistance. Cell
Metab. 16:765–776. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Uchiumi T and Kang D: The role of
TFAM-associated proteins in mitochondrial RNA metabolism. Biochim
Biophys Acta. 1820:565–570. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Wallace DC and Fan W: The pathophysiology
of mitochondrial disease as modeled in the mouse. Genes Dev.
23:1714–1736. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Han B, Izumi H, Yasuniwa Y, et al: Human
mitochondrial transcription factor A functions in both nuclei and
mitochondria and regulates cancer cell growth. Biochem Biophys Res
Commun. 408:45–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Guo J, Zheng L, Liu W, et al: Frequent
truncating mutation of TFAM induces mitochondrial DNA depletion and
apoptotic resistance in microsatellite-unstable colorectal cancer.
Cancer Res. 71:2978–2987. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Groblewska M, Siewko M, Mroczko B and
Szmitkowski M: The role of matrix metalloproteinases (MMPs) and
their inhibitors (TIMPs) in the development of esophageal cancer.
Folia Histochem Cytobiol. 50:12–19. 2012. View Article : Google Scholar
|
|
25.
|
Rietz A and Spiers J: The relationship
between the MMP system, adrenoceptors and phosphoprotein
phosphatases. Br J Pharmacol. 166:1225–1243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Mannello F and Medda V: Nuclear
localization of matrix metal-loproteinases. Prog Histochem
Cytochem. 47:27–58. 2012. View Article : Google Scholar
|
|
27.
|
Bauvois B: New facets of matrix
metalloproteinases MMP-2 and MMP-9 as cell surface transducers:
outside-in signaling and relationship to tumor progression. Biochim
Biophys Acta. 1825:29–36. 2012.PubMed/NCBI
|
|
28.
|
Siefert SA and Sarkar R: Matrix
metalloproteinases in vascular physiology and disease. Vascular.
20:210–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
